Israel-Based Clearmind Medicine Successfully
Completes Production of CMND-100 Drug Candidate for Clinical
Trial
Tel Aviv, Israel /
Vancouver, Canada, Jan. 10, 2023 -- InvestorsHub NewsWire --
Clearmind Medicine Inc. (Nasdaq:
CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the
"company"), a biotech company focused on discovery and development
of novel psychedelic-derived therapeutics to solve major
undertreated health problems, announced that it has successfully
manufactured batches of its drug candidate, MEAI-based molecule
CMND-100, for use in its first in-human clinical trial.
The trial will evaluate the
psychedelic-derived drug candidate for the treatment of Alcohol Use
Disorder (AUD).
"Having our drug candidate
ready to be tested is a major milestone toward our first in-human
clinical trial," said Dr. Adi Zuloff-Shani, Clearmind's Chief
Executive Officer. "Our pre-clinical positive results indicated the
potential of our unique treatment for AUD. We continue to execute
the final steps necessary in order to commence our clinical
program."
The drug candidate was
produced under GMP (Good Manufacturing Process) conditions to
comply with FDA requirements.
About Clearmind
Medicine Inc.
Clearmind is a psychedelic
pharmaceutical biotech company focused on the discovery and
development of novel psychedelic-derived therapeutics to solve
widespread and underserved health problems, including alcohol use
disorder. Its primary objective is to research and develop
psychedelic-based compounds and attempt to commercialize them as
regulated medicines, foods or supplements.
The Company's intellectual
portfolio currently consists of seven patent families. The Company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its portfolio.
Shares of Clearmind are
listed for trading on Nasdaq under the symbol "CMND", the Canadian
Securities Exchange under the symbol "CMND" and the Frankfurt Stock
Exchange under the symbol "CWY".
For further information,
please contact:
Investor Relations,
Email:
invest@clearmindmedicine.com
Telephone: (604)
260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING
STATEMENTS:
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act and other securities laws. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. For
example, the Company is using forward-looking statements when it
discusses clinical batches production of its novel
psychedelic-derived drug candidate, the Company's upcoming FIH
clinical trial, and any future correspondence with the FDA.
Forward-looking statements are not historical facts, and are based
upon management's current expectations, beliefs and projections,
many of which, by their nature, are inherently uncertain. Such
expectations, beliefs and projections are expressed in good faith.
However, there can be no assurance that management's expectations,
beliefs and projections will be achieved, and actual results may
differ materially from what is expressed in or indicated by the
forward-looking statements. Forward-looking statements are subject
to risks and uncertainties that could cause actual performance or
results to differ materially from those expressed in the
forward-looking statements. For a more detailed description of the
risks and uncertainties affecting the Company, reference is made to
the Company's reports filed from time to time with the Securities
and Exchange Commission ("SEC"), including, but not limited to, the
risks detailed in the Company's final prospectus (registration No.
333-265900) filed with the SEC on November 16, 2022.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
